<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00430001</url>
  </required_header>
  <id_info>
    <org_study_id>HERNATA</org_study_id>
    <nct_id>NCT00430001</nct_id>
  </id_info>
  <brief_title>Vinorelbine Plus (+) Trastuzumab vs Docetaxel Plus (+) Trastuzumab as 1 Line Treatment for HER2 Positive (+) Metastatic Breast Cancer</brief_title>
  <official_title>A Randomised Phase III Study of Trastuzumab-Docetaxel vs Trastuzumab-Vinorelbine as 1. Line Therapy for Patients With Metastatic HER2 Positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Breast Cancer Cooperative Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Danish Breast Cancer Cooperative Group</source>
  <brief_summary>
    <textblock>
      In an open-label randomised phase III-trial patients with metastatic HER2-positive breast
      cancer naive to chemotherapy with normal organ function and WHO performance status &lt; 3 are
      randomised to receive either docetaxel 100 mg/m2 i.v. plus trastuzumab 6 mg/kg (8 mg/kg
      loading dose) q 3 weeks or vinorelbine 30 or 35 mg/m2 days 1+8 plus trastuzumab 6 mg/kg (8
      mg/kg loading dose) q 3 weeks. Primary endpoint is time to progression. Secondary endpoints
      include overall survival, time to treatment failure, response rate, duration of response and
      toxicity. The study hypothesis is that docetaxel is more efficient than vinorelbine but also
      more toxic.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2005</start_date>
  <completion_date type="Anticipated">December 2008</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>median</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>response rate, overall survival, toxicity</measure>
    <time_frame>Median</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinorelbine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Locally advanced or metastatic HER2-positive breast cancer

          -  WHO performance status &lt; 3

        Exclusion Criteria:

          -  Chemotherapy for metastatic breast cancer or adjuvant therapy within 12 months with
             docetaxel, vinorelbine or trastuzumab

          -  Severe dyspnoea

          -  Abnormal organ function including cardiac
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Andersson, MD D Med Sci</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Oncology 5074, Rigshospitalet, 2100 Copenhagen, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Andersson, MD D Med Sci</last_name>
    <phone>+45 35458105</phone>
    <email>michael.andersson@dadlnet.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Oncology, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2007</study_first_submitted>
  <study_first_submitted_qc>January 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2007</study_first_posted>
  <last_update_submitted>May 6, 2008</last_update_submitted>
  <last_update_submitted_qc>May 6, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2008</last_update_posted>
  <keyword>Metastatic breast neoplasm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

